Caffeine is the most widely consumed psychoactive substance in the world and presents with wide interindividual variation in metabolism. This variation may modify potential adverse or beneficial effects of caffeine on health. We conducted a genome-wide association study (GWAS) of plasma caffeine, paraxanthine, theophylline, theobromine and paraxanthine/caffeine ratio among up to 9,876 individuals of European ancestry from six population-based studies. A single SNP at 6p23 (near CD83) and several SNPs at 7p21 (near AHR), 15q24 (near CYP1A2) and 19q13.2 (near CYP2A6) met GW-significance (P<5×10 -8 ) and were associated with one or more metabolites. Variants at 7p21 and 15q24 associated with higher plasma caffeine and lower plasma paraxanthine/caffeine (slow caffeine metabolism) were previously associated with lower coffee and caffeine consumption behavior in GWAS. Variants at 19q13.2 associated with higher plasma paraxanthine/caffeine (slow paraxanthine metabolism) were also associated with lower coffee consumption in the UK Biobank (n=94,343, P<1.0 × 10 -6 ). Variants at 2p24 (in GCKR), 4q22 (in ABCG2) and 7q11.23 (near POR) that were previously associated with coffee consumption in GWAS were nominally associated with plasma caffeine or its metabolites. Taken together, we have identified genetic factors contributing to variation in caffeine metabolism and confirm an important modulating role of systemic caffeine levels in dietary caffeine consumption behavior. Moreover, candidate genes identified encode proteins with important clinical functions that extend beyond caffeine metabolism.
Introduction
Caffeine (1,3,7 trimethylxanthine, 137X) is the most widely consumed psychoactive substance in the world (1). While naturally present in coffee, tea and chocolate, caffeine is also increasingly added to a variety of foods and beverages and this has fostered interest and concern regarding potential health effects of caffeine in the diet (1, 2).
It is well known that there is wide interindividual variation in caffeine metabolism and this may modify potential adverse or beneficial health effects of dietary caffeine (3-5). After its oral intake, caffeine is completely absorbed, rapidly distributed and extensively metabolized in the liver to three major metabolites: paraxanthine (1,7 dimethylxanthine [17X]), theophylline Clinical pharmacokinetic studies have identified a number of environmental and biological factors impacting caffeine metabolism and, more specifically, its CYP1A2-mediated metabolism (5-7, 9). However, much of the variation in caffeine metabolism is heritable and clinical studies have limited power in identifying the precise genetic factors (6, 9). Populationbased genome-wide association studies (GWAS) have identified eight loci associated with selfat King's College London on October 18, 2016 http://hmg.oxfordjournals.org/ Downloaded from reported coffee and caffeine intake (10, 11). The most prominent loci map near AHR and CYP1A2, which code for biological candidate proteins involved in caffeine metabolism.
Moreover, GWAS of the human metabolome identified a significant association between crosssectional measures of plasma caffeine levels and the same loci near AHR (12, 13). In the current study, we build on our previous work to identify loci associated with different aspects of caffeine metabolism in a larger sample and with a more comprehensive analysis of the caffeine metabolic pathway. The results are additionally mined to gain insight to loci previously associated with dietary caffeine intake behavior.
Results

Genome-wide association studies
We performed a meta-analysis of GWAS summary statistics from six population-based studies of European ancestry to detect single-nucleotide polymorphisms (SNPs) that are associated with plasma 137X, 17X, 13X, 37X, 1,3,7-trimethyluric acid (137U) and the plasma ratio: 17X/137X (Supplementary Table S1 -S3, Figure 1 ). Study participant characteristics closest to the time of blood collection are presented in Supplementary Table S2 . Overall, men (36%) and women (64%) were aged ~48 to 71 years and 17% reported currently smoking. GW-significant SNPs were identified for 137X (n=25), 17X (n=1), 13X (n=1) and 17X/137X (n=103), and together mapped to 22 independent SNPs (defined as r 2 <0.3 or distance >500 kb) in four genomic regions (Table 1, Supplementary Table S4 , Figure S1 -S8). Within two of the four candidate regions, 7p21 and 19q13.2, we identified 13 GW-significant indel associations with 17X/137X
(Supplementary Table S5 ). Four of these indels did not correlate with GW-significant SNPs in these regions (Table 1) . Heterogeneous allelic effects (I 2 >50%) were observed at 7p21 and Table S6 ).
Follow-up metabolite analysis
All top index SNPs and indels were followed up in several of the participating studies for association testing with the same or related metabolites and ratios in plasma and urine (Supplementary Table S3 ). Table 2 summarizes the results of these analyses while details are provided in Supplementary Tables S4 and S7 . Patterns of associations consistent with respective plasma metabolites and/or proximity in the caffeine metabolic pathways were observed. We also tested SNP associations with plasma levels of trigonelline (Trig) and quinine (QN), both unrelated to caffeine, but correlated with coffee intake (4 Table S9 ).
Potential SNP-function
Putative causal variants in cell types of action and target genes were predicted for GW-confirmed loci (Table 1) Overlap of loci for caffeine metabolites and coffee consumption behavior 
Discussion
In the current study, we leverage the existing knowledge of caffeine pharmacology and power of large population-based -omics studies to identify loci associated with plasma levels of caffeine metabolites in humans. Despite the absence of data concerning recent caffeine intake prior to sample collection, we identified three genomic regions mapping to biologically relevant candidate genes. Our study also informs about mechanisms of SNPs identified in our previous GWAS of coffee consumption and, in turn, confirms an important modulating role of systemic caffeine levels in dietary caffeine consumption behavior.
Consistent with the major role of CYP1A2 in caffeine metabolism (3, 8, 16), SNPs near CYP1A2 were significantly associated with 17X/137X and 137X levels as well as several other caffeine metabolites measured in plasma or urine. The most significant index SNP (rs2472297) maps to the bidirectional promoter region of CYP1A1 and CYP1A2, where known AHRE reside.
The aryl hydrocarbon receptor (Ahr) plays an important role in CYP1A2 expression (17) , and its gene is also the only candidate residing at 7p21, where up to 6 SNPs correlate with plasma 17X/137X and 137X. All alleles at 7p21 and 15q24 that were associated with lower 17X/137X
were associated with higher 137X levels, suggesting they are associated with slow caffeine metabolism. Individuals with these particular alleles may require less caffeine than individuals with the alternate alleles to achieve or maintain the levels needed for the optimal psychostimulant effects of caffeine. Their threshold for adverse effects of caffeine may also be lower. Indeed, the same alleles were associated with lower caffeine and coffee consumption in previous GWAS (10, 11) and in the UK Biobank in the present study.
The most plausible candidate at 19q13.2 associated with 17X/137X is CYP2A6. Based on existing knowledge, however, CYP2A6 does not catalyze the demethylation of 137X to 17X, but rather hydroxylates 17X to 17U (Figure 1 ). The latter metabolic step is responsible for only 10-20% of 17X clearance and is also catalyzed by CYP1A2 and xanthine dehydrogenase, but to a lesser extent relative to CYP2A6 (3, 8, 18, 19) . The association between CYP2A6 variation and 17X/137X is likely an indirect result of altered 17X metabolism. Indeed, CYP2A6 variants linked to higher 17X/137X were associated with higher 17X and lower plasma and urine 17U/17X ratio (a measure of CYP2A6 activity (20)), but presented with no association with 137X.
Pharmacokinetic studies also report associations between CYP2A6 variation and urine 17U/17X
and (5-acetylamino-6-amine-3-methyluracil + 1-methylxanthine + 1-methyluric acid )/17U
(originally described as an index of CYP1A2 activity (18, 21, 22 ). Our interpretation is further supported by the literature pertaining to CYP2A6 variation and nicotine metabolism. Up to 75%
of nicotine is converted to cotinine (COT) mainly by CYP2A6 and most of COT is converted to A single SNP at 6p23 near CD83 was significantly associated with 17X. Although associations between this SNP and other plasma and urine caffeine metabolites were also observed, a plausible link between the 6p23 locus and caffeine metabolism is unknown.
Variation in other candidate genes involved in caffeine metabolism or CYP450 regulation did not yield statistically significant associations. It is possible that these genes have less common functional SNPs or very modest effects on plasma caffeine metabolite levels that warrant a larger sample size to detect.
In addition to loci near CYP1A2 and AHR discussed above, the CCGC identified six additional SNPs associated with coffee consumption (Table 2) . rs17685 maps to the 3'UTR of POR, encoding P450 oxidoreductase which transfers electrons to all microsomal CYP450s enzymes (29). Given this function and the observation that the rs17685 C variant associated with lower coffee consumption (11) was nominally associated with higher plasma caffeine levels, the mechanism linking this variant to coffee consumption behavior may be similar to that of AHR and CYP1A2, as discussed above.
rs1481012 at 4q22 maps to ABCG2, encoding a xenobiotic efflux transporter. The more frequent rs1481012 A allele previously linked with higher coffee consumption was nominally associated with higher plasma levels of 137X, 17X and 13X compared to the minor G allele. The rs1260326 is a nonsynonymous and functional SNP in GCKR that has previously been associated with over 25 other metabolic traits(36). GCKR is expressed nearly exclusively in the liver and encodes glucokinase regulatory protein (GKRP). We previously postulated that GCKR SNP alters methylation of PPM1G; a putative regulatory target for Ahr and binding target for PPP1R1B, which mediates psychostimulant effects of caffeine(11, 37). To our knowledge, GKRP has no known role in caffeine or xenobiotic metabolism yet the results of the current study do not rule out the possibility. rs1260326 was strongly associated with 17X/137X and patterns of associations with caffeine metabolites and coffee drinking behavior were similar to those for AHR, CYP1A2 and POR (Table 2) . Future larger studies are warranted to further disentangle the association of the GCKR locus with coffee intake and caffeine metabolism.
Variants near 7q11.23, 11p13 and 17q11.2 map near genes including MLXIPL, BDNF and SLC6A4, respectively, with no known role in caffeine metabolism but possibly roles in response to caffeine psychostimulant effects. Although alleles at these loci linked to increased intake may have theoretically been associated with higher caffeine levels, no SNP-metabolite associations
were observed in the current study.
SNPs near AHR associated with higher coffee consumption were also associated with higher decaffeinated coffee consumption in the CCGC study (11). This finding was replicated in the current analysis of the UK Biobank, but similar patterns of associations also extended to variants near CYP1A2, ABCG2, MLXIPL, and POR. These associations may be the result of Pavlovian conditioning among former regular coffee consumers or perhaps the small amounts of caffeine in decaffeinated coffee (1). These genetic factors may therefore be good markers of early or lifetime dietary caffeine exposure. clinical pharmacokinetic studies are thus warranted and the current study represents an efficient first step that will narrow these more detailed efforts to SNPs with potential clinical significance.
Materials and Methods
Study samples
Studies contributing to the GWAS of caffeine metabolites have been described in detail 
metabolite profiling was performed using UPLC-MS/MS (ULSAM, PIVUS, TwinGene, SKIPOGH) or UPLC-ESI-MS/MS (SHIP-TREND and
TwinsUK). Technical, water, and spiked-standard controls were analyzed in parallel with study samples. For each metabolite examined in the current study, samples with values of 0 were excluded as were data points more than 4 standard deviations from the median concentration.
Each study applied a different method for normalizing the distribution of the metabolites and 17X/137X (Supplementary Table S2 ). To facilitate meta-analysis all data were rescaled to have a mean of 0 and standard deviation of 1 prior to study-specific GW analysis.
Plasma QN, Trig and additional caffeine metabolites addressed in follow-up analysis were measured in TwinsUK or SHIP-TREND. Urine measures of eight caffeine-related metabolites were available in SHIP-TREND and four of these were also available in SKIPOGH.
Urine metabolites were measured by the same methods used for plasma measures but with modification to sample preparation and pre-processing (Supplementary Table S2-S3) . Data were normalized and standardized as described above for plasma metabolites and 17X/137X prior to study-specific GW analysis.
Genotyping, quality control and imputation DNA was extracted from blood samples using conventional methods. Details of the genotyping process and QC for each study population have been described previously and also detailed in Supplementary (49) . Imputation results are summarized as an "allele dosage" (a fractional value between 0 and 2), defined as the expected number of copies of a specified allele at that SNP.
UK Biobank
To complement previously published GWAS of coffee intake behavior (see below), we performed new candidate SNP association studies of coffee intake behavior in the UK Biobank, 1000G phase 3 reference panels as described previously (52, 53).
Statistical analysis
Genome-wide association studies: Each study performed GWA-testing for each metabolite or ratio across up to ~31 million SNPs and indels, based on linear regression under an additive genetic model. Analyses were adjusted for smoking status and, when applicable, age, sex, studysite, fasting status, family structure and/or study-specific principal components of population substructure (Supplementary Table S2 ).
Prior to meta-analysis, we removed SNPs with a minor allele frequency <0.01 or imputation quality information score <0.4. Fixed effects meta-analyses were performed with METAL (54) using p-values and effective sample size for each study. The software also calculates the genomic control (λ) value for each study and then adjusts each study's results using the corresponding λ value. Supplementary Table S2 provides metabolite-and study-specific summaries pertaining to number of SNPs contributing to the meta-analysis and λ values. Only SNP-metabolite associations based on data from at least two studies were used to generate
Manhattan, quantile-quantile, and regional association plots, and for pathway and gene-based Potential SNP function: All confirmed index SNPs and their correlated proxies (r 2 >0.8) were systematically mined for putative causal variants, eQTLs, cell types, regulators and target genes using publicly available resources; a process facilitated by Haploreg v4 (57) . The latter was also used for enhancer enrichment analysis using the 15-state ChromHMM core model, H3K4me1 peaks and H3K27ac peaks (57) . The overlap with enhancers in each cell type was compared to two background models to assess enrichment: all 1000 Genomes variants with a frequency above 5% in any population and all independent GWAS catalog SNPs. The enrichment relative to these 
Overlap of loci for caffeine metabolites and coffee consumption behavior:
Metabolite associations with SNPs previously associated with coffee consumption in the Coffee and Caffeine Genetics Consortium (CCGC) GWAS (11) were also detected in the current study.
Since the CCGC GWAS was based on HapMap II, the complementary look-up (i.e. SNPs associated with metabolites) was incomplete. Therefore, de novo candidate SNP analysis of the UK Biobank cohort was performed following the same linear regression models used in the GWAS of coffee intake (cups/d among coffee drinkers). Age, sex, genotype array, smoking status and ten principal components were included in the regression model and was restricted to unrelated individuals of European Ancestry with high quality genetic data (N=94,343) following guidelines provided by the UK Biobank Coordinating Centre(58).
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Legends to Figures
Figure 1
Our current understanding of caffeine metabolism in humans. Metabolites underlined are amongst those examined in the current study. 137X: 1,3,7-trimethylxanthine (caffeine); 17X: 1,7-dimethylxanthine (paraxanthine); 13X: 1,3-dimethylxanthine (theophylline); 37X: 3,7-dimethylxanthine (theobromine); 137U:1,3,7-trimethyluric acid; 17U: 1,7-dimethyluric acid; 13U:1,3-dimethyluric acid; 37U: 3,7-dimethyluric acid; 1MX: 1-methylxanthine; 3MX: 3-methylxanthine; 7MX: 7-methylxanthine; 1MU: 1-methyluric acid; 3MU: 3-methyluric acid; 7MU: 7-methyluric acid; AFMU: 5-acetylamino-6-formylamino-3-methyluracil. Data from (7, 8). rs66500423  rs4803373  rs78011401  rs11668399  rs56113850  rs56267346  rs28399442  rs67210567  rs7260629  rs5828081  rs200292835  rs28602288  rs79600176  rs184589612  rs72480748  rs10425738 EA, effect allele; NEA, non-effect allele; EAF, effect allele frequency; 137X: 1,3,7-trimethylxanthine (caffeine); 17X: 1,7-dimethylxanthine (paraxanthine); 13X: 1,3-dimethylxanthine (theophylline); 37X: 3,7-dimethylxanthine (theobromine); 137U: 1,3,7-trimethyluric acid a SNPs for each trait were independently pruned for LD. Thus, r 2 between trait-specific index-SNPs may exceed our threshold for defining 'independent' SNPs (r 2 <0.3, 500kb).
b Standardized (Z) scores representing an increase/decrease in plasma metabolite level per effect allele, and corresponding P-values from fixed-effects meta-analysis. c Significant heterogeneity in allelic effects (I
